RESCENE Medical Signs Exclusive Distribution Agreement with INFIX in Japan... Beauty Device "COOLOA 600" Makes B2B Global Debut

Exclusive Supply Agreement for COOLOA 600 Signed with Japanese Distributor INFIX Inc., Securing First Overseas B2B Channel
Expanding Consumer Reach in Japan by Participating in Tokyo B2C Event on November 3

RESCENE Medical, a company specializing in cryogenic medical devices (Co-CEOs Gunho Kim and Uigyung Choi), announced on September 17 that it has signed an exclusive distribution agreement with INFIX Inc. (CEO Atsumasa Yoshida), a local distribution specialist, to supply its home beauty device "COOLOA 600" to the Japanese market.

Until now, RESCENE Medical has focused on B2B business with its dermatology medical device TargetCool and veterinary medical device VetEase. In contrast, its home beauty device COOLOA 600 was first introduced to the domestic B2C market in July. This agreement with INFIX marks the first time COOLOA 600, initially launched as a B2C product, will enter a B2B global distribution network, demonstrating RESCENE Medical’s diversification strategy by organically expanding domestic and overseas channels according to product line strategies.

COOLOA 600 is a premium home beauty device based on RESCENE Medical’s proprietary precision cryogenic technology, PIPD (Picoliter Ice Particle Delivery). Beginning with a launch on Naver Smart Store in July, followed by the company’s own online mall and home shopping channels, RESCENE Medical has continued to expand COOLOA 600’s sales channels in the domestic B2C market.

Under this agreement, INFIX has secured the exclusive rights to distribute COOLOA 600 in Japan. The company plans to launch the product through a comprehensive distribution network that spans its affiliate B'ELLA BI INC., online brand malls, e-commerce platforms, offline retail stores, TV and catalog channels, as well as specialist medical beauty channels such as plastic surgery clinics, dermatology clinics, and aesthetic salons.

The Japanese home beauty device market, like Korea, is experiencing a rapid increase in consumers seeking professional-level skincare at home, and this new market entry is seen as closely aligned with the needs of local consumers.

INFIX will also showcase COOLOA 600 directly to Japanese consumers on November 3 at the "LULA SUMMIT 2026," set to take place at Bellesalle Shibuya Garden in Shibuya, Tokyo. This event, hosted by the local beauty clinic LULA, is an annual medical beauty festival that gathers thousands of visitors, providing COOLOA 600 with an opportunity to broaden its local consumer contact points and boost brand recognition.

A RESCENE Medical representative stated, "The agreement with INFIX is highly significant as it represents the first overseas B2B partnership for COOLOA 600," and added, "Starting with Japan, we will continue to expand COOLOA 600’s global B2B distribution network."

Meanwhile, RESCENE Medical is a KOSDAQ-listed company with a portfolio spanning medical, veterinary, and beauty fields based on precision cryogenic technology and plans to continue expanding its business across both domestic and international B2B and B2C channels with this agreement as a momentum.

This content was produced with the assistance of AI translation services.